Transcatheter vs Surgical Replacement of Degenerated Bioprosthetic Aortic Valve: A Meta-Analysis of Propensity-Score-Matched Studies.
Pouya Ebrahimi, Maryam Taheri, Mehrdad Mahalleh et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis compared transcatheter valve-in-valve implantation (ViV-TAVR) to redo surgical aortic valve replacement (redo-SAVR) in 16,223 patients. ViV-TAVR was associated with significantly lower short-term all-cause mortality (RR: 0.47; 95% CI: 0.34-0.66; p<0.0001) and shorter hospital stays, indicating its advantages as a less invasive option for treating degenerated bioprosthetic aortic valves.
Key findings
- ViV-TAVR showed a 53% reduction in short-term all-cause mortality compared to redo-SAVR (RR: 0.47).
- Major bleeding occurred significantly less in the ViV-TAVR group (RR: 0.45).
- ViV-TAVR was associated with a 44% lower risk of acute kidney injury (RR: 0.56).
- Patients undergoing ViV-TAVR had shorter hospital stays (SMD: -0.79).
Why it matters
The findings suggest that ViV-TAVR may provide significant short-term benefits over traditional redo-SAVR, potentially influencing treatment decisions for patients with degenerated bioprosthetic aortic valves. Understanding these outcomes can help clinicians optimize patient care.